Myval Beyond the Aortic Valve: Device–Anatomy Interaction, Procedural Strategy, and Clinical Evidence in Mitral, Tricuspid, and Pulmonary Positions
Authors:
Preprint
- 29 July 2026
- preprint
- Published by MDPI AG in Preprints.org
Abstract
The Myval balloon-expandable transcatheter heart valve was developed for transcatheter aortic valve implantation, but its broad 20–32-mm size matrix and controlled deployment have prompted use in non-aortic landing zones. This narrative review critically synthesizes Myval-specific case reports, case series, and observational cohorts, together with relevant platform-level evidence, addressing device design, anatomical selection, imaging, procedural strategy, clinical outcomes, and evidence gaps. Reported applications include mitral valve-in-valve, valve-in-ring, and valve-in-mitral annular calcification; tricuspid valve-in-valve and valve-in-ring; and pulmonary implantation in conduits, surgical bioprostheses, and selected native or patched right ventricular outflow tracts. Outcomes appear most predictable within circular stented surgical bioprostheses, whereas non-circular rings, severe mitral annular calcification, and compliant or aneurysmal outflow tracts present greater risks of inadequate anchoring, paravalvular regurgitation, embolization, frame deformation, left ventricular outflow tract obstruction, and coronary compression. Intermediate and extra-large sizes may facilitate closer dimensional matching, but comparative advantage has not been established. The available data document procedural feasibility in anatomically selected patients but are predominantly observational, with limited independent adjudication and follow-up. These procedures are generally off-label and should remain individualized Heart Team decisions; prospective multicenter studies are required to define comparative safety, antithrombotic management, durability, and lifetime reintervention strategies.Keywords
All Related Versions
- Version 1, 2026-07-29, Preprints
- Published version: Bioengineering, 13 (9), 957.
This publication has 57 references indexed in Scilit:
- Percutaneous Pulmonary Valve Implantation In Native Right Ventricular Outflow Tract Using Myval™ Without Pre‐StentingHealth Science Reports, 2025
- Multicenter Experience for Early and Mid-Term Outcome of MyVal Transcatheter Pulmonary Valve ImplantationPediatric Cardiology, 2024
- Safety and effectiveness of the novel Myval Octacor transcatheter heart valve in severe, symptomatic aortic valve stenosis — A real-world Indian experience (The OCTACOR India Study)Cardiovascular Revascularization Medicine, 2024
- Clinical Outcomes Following Transcatheter Mitral Valve-in-Valve Replacement Using a Meril Myval Transcatheter Heart ValveHeart, Lung and Circulation, 2024
- Performance of the 32 mm Myval transcatheter heart valve for treatment of aortic stenosis in patients with extremely large aortic annuli in real‐world scenario: First global, multicenter experienceCatheterization and Cardiovascular Interventions, 2023
- Transcatheter Tricuspid Valve-in-Valve Implantation With a Novel Balloon Expandable Myval THVThe Annals of Thoracic Surgery, 2021
- Pulmonary percutaneous valve implantation in large native right ventricular outflow tract with 32 mm Myval transcatheter heart valveCatheterization and Cardiovascular Interventions, 2021
- Transcatheter Valve-in-Valve Implantation With a Novel Balloon-Expandable Device in Patients With Bioprosthetic Heart Valve Failure: A Case SeriesCardiovascular Revascularization Medicine, 2021
- One-Year Outcomes of Mitral Valve-in-Valve Using the SAPIEN 3 Transcatheter Heart ValveJAMA Cardiology, 2020
- Transcatheter Valve Underexpansion Limits Leaflet Durability: Implications for Valve-in-Valve ProceduresAnnals of Biomedical Engineering, 2016